Karuna Therapeutics (KRTX) Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KRTX shares.
View KRTX analyst ratings or view top-rated stocks.

12 equities research analysts have issued 12-month target prices for Karuna Therapeutics' stock. Their KRTX share price forecasts range from $209.00 to $323.00. On average, they expect the company's share price to reach $260.50 in the next twelve months. This suggests a possible upside of 56.9% from the stock's current price.
View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts.

Karuna Therapeutics' stock was trading at $196.50 at the beginning of the year. Since then, KRTX shares have decreased by 15.5% and is now trading at $166.03.
View the best growth stocks for 2023 here.

Karuna Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 1,350,000 shares, a decline of 6.9% from the August 15th total of 1,450,000 shares. Based on an average trading volume of 345,500 shares, the days-to-cover ratio is presently 3.9 days.
View Karuna Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KRTX earnings forecast.

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($2.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.76) by $0.01. The business earned $0.10 million during the quarter, compared to analysts' expectations of $0.42 million. Karuna Therapeutics had a negative trailing twelve-month return on equity of 27.13% and a negative net margin of 2,795.96%. The business's revenue for the quarter was down 98.1% compared to the same quarter last year. During the same period last year, the business earned ($2.17) earnings per share.

ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Karuna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Capital International Investors (10.60%), BlackRock Inc. (4.95%), State Street Corp (2.16%), General Atlantic L.P. (1.93%), Geode Capital Management LLC (1.29%) and Alliancebernstein L.P. (1.02%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends.

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KRTX stock can currently be purchased for approximately $166.03.

Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $6.25 billion and generates $10.64 million in revenue each year. The company earns $-276,340,000.00 in net income (profit) each year or ($10.15) on an earnings per share basis.

The company employs 210 workers across the globe.

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com.